Donepezil Market (By Type: 5mg, 10mg, and 23mg; By Application: Hospitals, Clinics, and Drugstore; By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Industry Size, Share, Growth, Trends 2025 to 2034.
The global donepezil market, valued at USD 906.15 million in 2025, is projected to reach approximately USD 1,072.03 million by 2035. This steady growth, driven by increasing use in functional foods, nutraceuticals, and pharmaceuticals, is expected at a CAGR of 1.70%.
| Reports Attributes | Statistics |
| Market Size in 2025 | USD 906.15 Million |
| Market Size in 2026 | USD 921.55 Million |
| Market Size in 2032 | USD 1,019.64 Million |
| Market Size by 2035 | USD 1,072.03 Million |
| CAGR 2026 to 2035 | 1.70% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
The donepezil market is expanding steadily due to the rising geriatric population and the growing burden of neurodegenerative diseases. Donepezil, a cholinesterase inhibitor, plays a crucial role in improving memory and cognitive function in patients with mild to moderate Alzheimer’s. The market benefits from strong healthcare infrastructure in developed regions and the increasing availability of cost-effective generic formulations in emerging economies. However, limited efficacy in advanced stages of the disease and potential side effects such as nausea and insomnia act as key restraints. Moreover, competition from novel Alzheimer’s drugs and ongoing research into disease-modifying treatments may impact long-term demand.
Despite these challenges, opportunities exist in expanding therapeutic indications for donepezil, such as in vascular dementia and Parkinson’s-related cognitive decline. Growing healthcare investments and the rising focus on early diagnosis are also expected to enhance market penetration in the coming years.
The donepezil market is anticipated to grow more rapidly as pharmaceutical companies adopt artificial intelligence AI-driven approaches in drug discovery, clinical trial optimization, and patient stratification. Artificial intelligence enables faster analysis of biological data to identify responders and optimize dosage regimens for better therapeutic outcomes.
| Regions | Shares (%) |
| North America | 33.27% |
| Asia Pacific | 27.89% |
| Europe | 23.96% |
| LAMEA | 14.88% |
| Segments | Shares (%) |
| 5mg | 46.32% |
| 10mg | 38.91% |
| 23mg | 14.77% |
| Segments | Shares (%) |
| Hospitals | 41.18% |
| Clinics | 28.74% |
| Drugstore | 30.08% |
Published by Ajit Bansod
